Robert Sidney Rosenson

Search results

• Why Your First Year After Discontinuing a Statin Can Be Deadly

  Rosenson, R. S.

  5/09/24

  3 items of Media coverage

  Press/Media

• Fewer people may need statins to prevent heart disease – US study

  Rosenson, R. S.

  19/06/24

  1 item of Media coverage

  Press/Media

• Fewer people may need statins to prevent heart disease, new study suggests

  Rosenson, R. S.

  12/06/24

  1 item of Media coverage

  Press/Media

• New AI Tool Finds Rare Variants Linked to Heart Disease in 17 Genes

  Park, J., Rocheleau, G., Do, R. & Rosenson, R. S.

  11/06/24

  1 item of Media coverage

  Press/Media

• Triglyceride levels normalised by novel RNA interference therapy

  Rosenson, R. S.

  6/06/24

  1 item of Media coverage

  Press/Media

• Arrowhead's Plozasiran Reduces Triglyceride Rich Lipoproteins in Patients with Mixed Hyperlipidemia

  Rosenson, R. S.

  3/06/24

  1 item of Media coverage

  Press/Media

• -Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

  Rosenson, R. S.

  30/05/24

  2 items of Media coverage

  Press/Media

• Robert Rosenson, MD: ARCHES-2 and Zodasiran in Mixed Hyperlipidemia; Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

  Rosenson, R. S.

  30/05/24

  2 items of Media coverage

  Press/Media

• Robert Rosenson, MD: ARCHES-2 and Zodasiran in Mixed Hyperlipidemia

  Rosenson, R. S.

  30/05/24

  2 items of Media coverage

  Press/Media

• Mount Sinai Trial Shows RNA Inhibitor Safely Lowers Cholesterol

  Rosenson, R. S.

  30/05/24

  1 item of Media coverage

  Press/Media

• Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

  Rosenson, R. S.

  30/05/24

  1 item of Media coverage

  Press/Media

• Arrowhead Pharmaceuticals reports Phase 2 study data of Zodasiran in patients with hyperlipidemia

  Rosenson, R. S.

  30/05/24

  1 item of Media coverage

  Press/Media

• RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial

  Rosenson, R. S.

  30/05/24

  1 item of Media coverage

  Press/Media

• Zodasiran Reduces Triglycerides, ANGPTL3 in Mixed Hyperlipidemia in ARCHES-2 Trial; A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.

  Rosenson, R. S.

  29/05/24

  2 items of Media coverage

  Press/Media

• RNA inhibitor is shown safe and effective in reducing a wide range of cholesterol and triglyceride levels in the blood in Mount Sinai-led clinical trial

  Rosenson, R. S.

  29/05/24

  4 items of Media coverage

  Press/Media

• RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial

  Rosenson, R. S.

  29/05/24

  1 item of Media coverage

  Press/Media

• Diabetes, GLP-1, and Lipid Reduction

  Rosenson, R. S.

  29/05/24

  1 item of Media coverage

  Press/Media

• Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia; - Zodasiran significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins across all dose levels at Week 24; - Data presented at E

  Rosenson, R. S.

  29/05/24

  11 items of Media coverage

  Press/Media

• Triglycerides Down With ANGPTL3 RNA Interference Agent

  Rosenson, R. S.

  29/05/24

  1 item of Media coverage

  Press/Media

• RNA Inhibitor Is Shown Safe and Effective in Reducing a Wide Range of Cholesterol and Triglyceride Levels in the Blood in Mount Sinai-Led Clinical Trial

  Rosenson, R. S.

  29/05/24

  1 item of Media coverage

  Press/Media

• Zodasiran Reduces Triglycerides, ANGPTL3 in Mixed Hyperlipidemia in ARCHES-2 Trial

  Rosenson, R. S.

  29/05/24

  2 items of Media coverage

  Press/Media

• RNA inhibitor is shown safe and effective in reducing a wide range of cholesterol and triglyceride levels in the blood

  Rosenson, R. S.

  29/05/24

  1 item of Media coverage

  Press/Media

• Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

  Rosenson, R. S.

  28/05/24

  9 items of Media coverage

  Press/Media

• Evinacumab Reduces Lipids, Cholesterol in Hypercholsterolemia and Hypertriglyceridemia

  Rosenson, R. S.

  16/05/24

  2 items of Media coverage

  Press/Media

• Evinacumab Reduces Lipids, Cholesterol in Hypercholsterolemia and Hypertriglyceridemia; Data from a meta-analysis of evinacumab trials reveal significant reductions in cholesterol and other lipid markers among patients with dyslipidemia.

  Rosenson, R. S.

  16/05/24

  2 items of Media coverage

  Press/Media